A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL�, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered t
Read time: 1 mins
Last updated:6th Feb 2009
To evaluate the tolerability of the 9-valent HPV L1 VLP vaccine when administered to 16- to 26-year-old women.
|Study start date||2009-02-06|